Zentalis Pharmaceuticals (NASDAQ:ZNTL) Issues Quarterly Earnings Results

Zentalis Pharmaceuticals (NASDAQ:ZNTL) released its earnings results on Wednesday. The company reported ($0.66) earnings per share for the quarter, topping the consensus estimate of ($0.75) by $0.09, Zacks reports. The company had revenue of $26.90 million during the quarter.

Zentalis Pharmaceuticals Price Performance

Shares of ZNTL stock traded up $0.03 during trading hours on Thursday, reaching $1.79. The stock had a trading volume of 1,010,820 shares, compared to its average volume of 1,520,523. The firm has a market capitalization of $127.56 million, a PE ratio of -0.72 and a beta of 1.75. The firm has a 50-day simple moving average of $2.06 and a 200-day simple moving average of $2.87. Zentalis Pharmaceuticals has a twelve month low of $1.61 and a twelve month high of $16.27.

Insider Buying and Selling at Zentalis Pharmaceuticals

In other Zentalis Pharmaceuticals news, insider Ingmar Bruns purchased 20,000 shares of Zentalis Pharmaceuticals stock in a transaction on Thursday, February 6th. The stock was bought at an average price of $2.28 per share, for a total transaction of $45,600.00. Following the transaction, the insider now owns 36,629 shares of the company’s stock, valued at $83,514.12. The trade was a 120.27 % increase in their position. The transaction was disclosed in a filing with the SEC, which is accessible through this link. Also, Director Jan Skvarka purchased 60,000 shares of the stock in a transaction dated Friday, January 31st. The shares were acquired at an average cost of $1.72 per share, for a total transaction of $103,200.00. Following the completion of the acquisition, the director now directly owns 149,551 shares of the company’s stock, valued at approximately $257,227.72. This trade represents a 67.00 % increase in their position. The disclosure for this purchase can be found here. 3.60% of the stock is currently owned by company insiders.

Analyst Upgrades and Downgrades

Several analysts recently weighed in on ZNTL shares. Wedbush reissued a “neutral” rating and issued a $4.00 price objective on shares of Zentalis Pharmaceuticals in a report on Friday, January 24th. UBS Group lowered their price target on Zentalis Pharmaceuticals from $5.00 to $2.20 and set a “neutral” rating for the company in a report on Tuesday, January 28th. HC Wainwright restated a “buy” rating and set a $10.00 price objective on shares of Zentalis Pharmaceuticals in a research note on Thursday. Finally, Wells Fargo & Company lowered their target price on shares of Zentalis Pharmaceuticals from $8.00 to $6.00 and set an “equal weight” rating for the company in a research note on Thursday, January 30th. Five equities research analysts have rated the stock with a hold rating and four have given a buy rating to the company. Based on data from MarketBeat.com, the stock currently has a consensus rating of “Hold” and an average target price of $8.24.

About Zentalis Pharmaceuticals

Zentalis Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, focuses on discovering and developing small molecule therapeutics for the treatment of various cancers. Its products candidatures include the ZN-c3, an inhibitor of WEE1, a protein tyrosine kinase for the treatment of inhibitor for advanced solid tumors and hematological malignancies; in Phase 2 clinical trial as a monotherapy for the treatment of uterine serous carcinoma indications; Phase 2 clinical trial in Cyclin E1 driven high-grade serous ovarian cancer, fallopian tube, or primary peritoneal cancer; Phase 1/2 clinical trial in combination with PARPi for platinum-resistant ovarian cancer; Phase 1b clinical trial in combination with chemotherapy in platinum-resistant ovarian, and peritoneal or fallopian tube cancer; Phase 1/2 clinical trial in combination with chemotherapy in relapsed or refractory osteosarcoma; Phase 1/2 clinical trial with encorafenib and cetuximab for mutant metastatic colorectal cancer; and Phase 1/2 clinical trial in combination with chemotherapy in pancreatic cancer.